EU/3/14/1244: Orphan designation for the treatment of polycythaemia vera

Ruxolitinib

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2015 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 19 February 2014, orphan designation (EU/3/14/1244) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for ruxolitinib for treatment of polycythaemia vera.

Key facts

Active substance
Ruxolitinib
Intended use
Treatment of polycythaemia vera
Orphan designation status
Withdrawn
EU designation number
EU/3/14/1244
Date of designation
19/02/2014
Sponsor

Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
Tel. +41 61 324 11 11 (Switzerland)
E-mail: orphan.enquiries@novartis.com

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2015 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
1 rating